
Kimberly Chong
Examiner (ID: 8669, Phone: (571)272-3111 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1636, 1635, 1674 |
| Total Applications | 2007 |
| Issued Applications | 1153 |
| Pending Applications | 209 |
| Abandoned Applications | 674 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18895519
[patent_doc_number] => 20240011004
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/271014
[patent_app_country] => US
[patent_app_date] => 2022-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44438
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271014
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/271014 | COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF | Jan 6, 2022 | Pending |
Array
(
[id] => 17548478
[patent_doc_number] => 20220119819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/570051
[patent_app_country] => US
[patent_app_date] => 2022-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570051
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/570051 | FORMULATION | Jan 5, 2022 | Abandoned |
Array
(
[id] => 19432871
[patent_doc_number] => 20240301369
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => POLYNUCLEOTIDE AND EXPRESSION CASSETTE COMPRISING CODING SEQUENCE OF TOLUENE DIOXYGENASE, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/260412
[patent_app_country] => US
[patent_app_date] => 2022-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9515
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260412
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/260412 | POLYNUCLEOTIDE AND EXPRESSION CASSETTE COMPRISING CODING SEQUENCE OF TOLUENE DIOXYGENASE, AND USE THEREOF | Jan 4, 2022 | Pending |
Array
(
[id] => 17546655
[patent_doc_number] => 20220117996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-21
[patent_title] => TRANS-SPLICING RIBOZYME TARGETING RHODOPSIN TRANSCRIPT AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/646244
[patent_app_country] => US
[patent_app_date] => 2021-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12503
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646244
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/646244 | Trans-splicing ribozyme targeting rhodopsin transcript and uses thereof | Dec 27, 2021 | Issued |
Array
(
[id] => 17561673
[patent_doc_number] => 20220125822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => Treatment Methods for Fibrosis Targeting SMOC2
[patent_app_type] => utility
[patent_app_number] => 17/645762
[patent_app_country] => US
[patent_app_date] => 2021-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17645762
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/645762 | Treatment methods for fibrosis targeting SMOC2 | Dec 22, 2021 | Issued |
Array
(
[id] => 19310493
[patent_doc_number] => 12036287
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-16
[patent_title] => Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes
[patent_app_type] => utility
[patent_app_number] => 17/559781
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 42
[patent_no_of_words] => 15236
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559781
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/559781 | Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes | Dec 21, 2021 | Issued |
Array
(
[id] => 17533892
[patent_doc_number] => 20220112501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/560080
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85823
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560080
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/560080 | Engineered immunostimulatory bacterial strains and uses thereof | Dec 21, 2021 | Issued |
Array
(
[id] => 19479789
[patent_doc_number] => 20240327831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 18/257547
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257547
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/257547 | COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY | Dec 21, 2021 | Pending |
Array
(
[id] => 17704966
[patent_doc_number] => 20220204972
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => Antisense oligonucleotides for the treatment of Stargardt disease
[patent_app_type] => utility
[patent_app_number] => 17/552372
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32331
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552372
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/552372 | Antisense oligonucleotides for the treatment of Stargardt disease | Dec 15, 2021 | Issued |
Array
(
[id] => 18020974
[patent_doc_number] => 20220372473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => ANTISENSE COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/553602
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553602
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553602 | ANTISENSE COMPOUNDS AND USES THEREOF | Dec 15, 2021 | Abandoned |
Array
(
[id] => 18938238
[patent_doc_number] => 20240033377
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => AAV VECTORS FOR GENE EDITING
[patent_app_type] => utility
[patent_app_number] => 18/266076
[patent_app_country] => US
[patent_app_date] => 2021-12-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 112059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -173
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266076
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/266076 | AAV VECTORS FOR GENE EDITING | Dec 8, 2021 | Pending |
Array
(
[id] => 17482575
[patent_doc_number] => 20220090079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/544801
[patent_app_country] => US
[patent_app_date] => 2021-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12325
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17544801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/544801 | Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors | Dec 6, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 17904269
[patent_doc_number] => 11458100
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => Lyophilization of RNA
[patent_app_type] => utility
[patent_app_number] => 17/542445
[patent_app_country] => US
[patent_app_date] => 2021-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 34065
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 261
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542445
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542445 | Lyophilization of RNA | Dec 4, 2021 | Issued |
Array
(
[id] => 18879465
[patent_doc_number] => 20240002834
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => ADENINE BASE EDITOR LACKING CYTOSINE EDITING ACTIVITY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/039632
[patent_app_country] => US
[patent_app_date] => 2021-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039632
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039632 | ADENINE BASE EDITOR LACKING CYTOSINE EDITING ACTIVITY AND USE THEREOF | Nov 30, 2021 | Pending |
Array
(
[id] => 17458725
[patent_doc_number] => 20220072029
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => BI SPECIFIC APTAMER
[patent_app_type] => utility
[patent_app_number] => 17/537195
[patent_app_country] => US
[patent_app_date] => 2021-11-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32413
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17537195
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/537195 | Bi specific aptamer | Nov 28, 2021 | Issued |
Array
(
[id] => 17996727
[patent_doc_number] => 11497814
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Compositions and methods of treating muscle atrophy and myotonic dystrophy
[patent_app_type] => utility
[patent_app_number] => 17/529197
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 69
[patent_figures_cnt] => 99
[patent_no_of_words] => 62670
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17529197
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/529197 | Compositions and methods of treating muscle atrophy and myotonic dystrophy | Nov 16, 2021 | Issued |
Array
(
[id] => 17460613
[patent_doc_number] => 20220073918
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
[patent_app_type] => utility
[patent_app_number] => 17/528383
[patent_app_country] => US
[patent_app_date] => 2021-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21899
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17528383
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/528383 | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat | Nov 16, 2021 | Issued |